"Evaxion's Breakthrough: AI-Driven Cancer Vaccine Boosts Stock by 30%"
Evaxion Biotech is leveraging AI-Immunology™ to develop tailored cancer vaccines targeting Endogenous Retroviruses (ERVs), an untapped source of tumor antigens, with the goal of providing treatment solutions to cancer patients unresponsive to conventional immunotherapy. The company aims to generate Proof-of-Concept data by the second half of 2024 and has presented recent insights at the American Society of Hematology Annual Meeting. ERVs, remnants of ancient viruses overexpressed in cancer, are promising targets for cancer vaccines, and AI-Immunology™ plays a crucial role in identifying therapeutically relevant ERV tumor antigens from genomic patient tumor data. Evaxion's AI-Immunology™ platform offers a scalable and adaptable approach to vaccine discovery for infectious diseases and cancers, revolutionizing the landscape of immunotherapy with personalized medicine.